Loading...
The Financial Express

Gilead prices remdesivir at $390 per vial in US

Published: June 29, 2020 18:27:24 | Updated: July 01, 2020 20:34:17


Gilead prices remdesivir at $390 per vial in US

Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.

Based on current treatment patterns, the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, reports Reuters citing the company.

 

Share if you like